SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

NCT05022654 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinomas

Interventions

DRUG: SI-B001
DRUG: Irinotecan

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.